Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Repertoire Immune Medicines has signed a partnership and licence agreement with Genentech, focusing on T cell-targeted immune ...

Biogen Netherlands has received marketing authorisation from the UK MHRA for its Skyclarys to treat Friedreich's ataxia.

Swiss oncology firm Veraxa Biotech is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare ...

EditCo Bio has entered a licensing agreement to secure access to Promega’s protein-tagging and bioluminescent identification ...

Contraception for women has seen little change over the past 50 years, with the most prevalent contraceptive pills containing ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

The expiration of the FDA’s paediatric priority review voucher programme is creating uncertainty for rare disease drug ...

ConcertAI has announced an agreement with Bayer that allows the latter to utilise its Translational360 and AI SaaS solutions.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting it exclusive rights to leverage its antibody ...